Management of hypoglycemic therapy in patients with type 2 diabetes mellitus and nephropathy

Abstract

Chronic kidney disease (CKD) is constantly increasing in terms of prevalence and incidence. Subjects with impaired renal function, even if only in the presence of micro/macroalbuminuria, have an increased cardiovascular risk profile. Therefore, we must pay particular attention to the treatment of all associated risk factors. Therapy with oral hypoglycemic agents often requires modulation of drug dosage based on kidney function. Today, there are molecules available that are able not only to induce cardiovascular protection, but also to slow the progression of renal damage.